Arkolith/Insider Trading/ATHA/Form 4

Renninger Robert

VP of FinanceAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Jan 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2025Sell(S)3K$0.56$2K90K
Dec 31, 2024Option exercise(M)12K—$093K
Nov 18, 2024Grant(A)4K$0.55$2K80K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)12K—$025K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-000527) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML